AbbVie Inc (ABBV) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$166.09 after a previous close of US$165.96. During the day the price has varied from a low of USD163.52 to a high of USD167.1. The latest price was USD163.93 (25 minute delay). AbbVie is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Best for day trading
Our top pick for
Dividend investing
| Open | US$166.09 |
|---|---|
| High | US$167.1 |
| Low | US$163.52 |
| Close | US$163.93 |
| Previous close | US$165.96 |
| Change | US$-2.03 |
| Change % | -1.2232% |
| Volume | 1,937,318 |
| 52-week range | US$127.9561 - US$181.1978 |
|---|---|
| 50-day moving average | US$164.6394 |
| 200-day moving average | US$160.6037 |
| Target price | US$184.08 |
| PE ratio | 51.0476 |
| Dividend yield | US$6.06 (3.61%) |
| Earnings per share (TTM) | US$3.36 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $163.93
| 1 week (2024-06-26) | -4.22% |
|---|---|
| 1 month (2024-06-03) | 2.33% |
| 3 months (2024-04-03) | -7.56% |
| 6 months (2024-01-03) | 2.16% |
| 1 year (2023-07-03) | 21.42% |
|---|---|
| 2 years (2022-07-01) | 6.59% |
| 3 years (2021-07-02) | 42.34% |
| 5 years (2019-07-03) | 118.69% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, AbbVie shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4488. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$26.1 billion (£20.5 billion).
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure stock profitability.
Over the last 12 months, AbbVie's shares have ranged in value from as little as US$127.9561 up to US$181.1978. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.582. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
| Revenue TTM | US$54.4 billion |
|---|---|
| Operating margin TTM | 28.29% |
| Gross profit TTM | US$41.5 billion |
| Return on assets TTM | 7.71% |
| Return on equity TTM | 56.24% |
| Profit margin | 11.02% |
| Book value | 4.535 |
| Market capitalisation | US$302.9 billion |
TTM: trailing 12 months
Dividend payout ratio: 55.93% of net profits
Recently AbbVie has paid out, on average, around 55.93% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.61% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 3.61% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $6.06 per share.
AbbVie's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
AbbVie's most recent dividend payout was on 14 August 2024. The latest dividend was paid out to all shareholders who bought their shares by 14 July 2024 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 12/31/2018) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
AbbVie Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 34.86 |
|---|---|
| Total ESG percentile | 65.78 |
| Environmental score | 4.96 |
| Environmental score percentile | 7 |
| Social score | 22.65 |
| Social score percentile | 7 |
| Governance score | 16.25 |
| Governance score percentile | 7 |
| Level of controversy | 3 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Steps to owning and managing Metals Acquisition Limited shares.
Steps to owning and managing Enlitic shares.
Steps to owning and managing Freightways shares.
Steps to owning and managing Blinklab shares.
We used Finder's proprietary algorithm to find the 10 best stocks under $10 on the ASX.
Looking for the best performing stocks in Australia? We update this list weekly.
We look at some of the biggest and best performing iron ore stocks in Australia.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Learn how to find the cheapest brokerage fees and a range of flexible trading features when you buy and sell US shares.
Should you trade shares from CommSec’s CDIA or stick with your own cash account? We compare the difference.